

Lale S TokgÄzoÄlu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/689597/publications.pdf>

Version: 2024-02-01

94
papers

30,845
citations

66336

42
h-index

37202

96
g-index

104
all docs

104
docs citations

104
times ranked

24757
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
2	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	2.2	2,767
3	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
4	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	2.2	2,393
5	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
6	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.8	1,753
7	Atherosclerosis. <i>Nature Reviews Disease Primers</i> , 2019, 5, 56.	30.5	1,601
8	Lipoprotein(a) as a cardiovascular risk factor: current status. <i>European Heart Journal</i> , 2010, 31, 2844-2853.	2.2	1,392
9	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.8	1,189
10	Statin-associated muscle symptoms: impact on statin therapyâ€”European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. <i>European Heart Journal</i> , 2015, 36, 1012-1022.	2.2	1,024
11	Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. <i>European Heart Journal</i> , 2011, 32, 1345-1361.	2.2	993
12	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.8 BT / Overlock 10 T	0.8	976
13	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
14	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	1.8	772
15	Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease. <i>Circulation</i> , 2018, 137, 338-350.	1.6	559
16	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	1.8	558
17	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.8	419
18	Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 0 0.8 BT / Overlock 10 T	0.8	410

#	ARTICLE	IF	CITATIONS
19	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
20	Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1141-1156.	2.8	272
21	Adverse effects of statin therapy: perception vs. the evidence â€” focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. <i>European Heart Journal</i> , 2018, 39, 2526-2539.	2.2	262
22	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.8	227
23	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. <i>European Heart Journal</i> , 2018, 39, 1131-1143.	2.2	171
24	Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. <i>JAMA Cardiology</i> , 2020, 5, 217.	6.1	169
25	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
26	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Lancet, The</i> , 2021, 398, 1713-1725.	13.7	142
27	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. <i>European Heart Journal</i> , 2017, 38, ehw480.	2.2	137
28	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 50-67.	11.4	114
29	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
30	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	6.8	101
31	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. <i>European Heart Journal</i> , 2022, 43, 830-833.	2.2	92
32	Obesity and cardiovascular risk. <i>Journal of Hypertension</i> , 2018, 36, 1427-1440.	0.5	86
33	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014, 15, 1-15.	1.2	83
34	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>European Journal of Preventive Cardiology</i> , 2017, 24, 4-40.	1.8	83
35	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.8	83
36	PCSK9 inhibition and inflammation: A narrative review. <i>Atherosclerosis</i> , 2019, 288, 146-155.	0.8	80

#	ARTICLE	IF	CITATIONS
37	Trends in Gender Differences in Cardiac Care and Outcome After Acute Myocardial Infarction in Western Sweden: A Report From the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	79
38	The gender gap in risk factor control: Effects of age and education on the control of cardiovascular risk factors in male and female coronary patients. The EUROASPIRE IV study by the European Society of Cardiology. <i>International Journal of Cardiology</i> , 2016, 209, 284-290.	1.7	77
39	Atrial Fibrillation After Coronary Artery Bypass Surgery: Predictors and the Role of MgSO ₄ Replacement. <i>Journal of Cardiac Surgery</i> , 1996, 11, 421-427.	0.7	56
40	Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels. <i>American Journal of Cardiology</i> , 2015, 115, 647-651.	1.6	54
41	Plasma interleukin-6 levels are increased in coronary artery ectasia. <i>Acta Cardiologica</i> , 2004, 59, 515-519.	0.9	53
42	The dawn of a new era of targeted lipid-lowering therapies. <i>European Heart Journal</i> , 2022, 43, 3198-3208.	2.2	48
43	Familial Hypercholesterolemia: Global Burden and Approaches. <i>Current Cardiology Reports</i> , 2021, 23, 151.	2.9	38
44	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.8	37
45	A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). <i>Atherosclerosis</i> , 2018, 270, 42-48.	0.8	30
46	Prevalence of potential familial hypercholesterolemia (FH) in 54,811 statin-treated patients in clinical practice. <i>Atherosclerosis</i> , 2016, 252, 1-8.	0.8	26
47	Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2019, 13, 455-467.	1.5	26
48	Pulmonary hypertension in Takayasu arteritis. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 1634-1639.	1.9	24
49	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1630-1636.	1.8	23
50	Functional exercise capacity, physical activity, and respiratory and peripheral muscle strength in pulmonary hypertension according to disease severity. <i>Journal of Physical Therapy Science</i> , 2015, 27, 1309-1312.	0.6	21
51	The association between circulating endothelial progenitor cells and coronary collateral formation. <i>Atherosclerosis</i> , 2011, 219, 851-854.	0.8	19
52	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 401-411.	1.4	18
53	Reprint of: Impact of Lipids on Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2980-2995.	2.8	17
54	Atherosclerotic Vascular Disease and Risk Factors in Turkey: From Past to Present. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 286-291.	2.0	16

#	ARTICLE	IF	CITATIONS
55	What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? <i>Atherosclerosis</i> , 2018, 277, 341-346.	0.8	15
56	Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 751-755.	1.5	14
57	The landscape of preventive cardiology in Turkey: Challenges and successes. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100184.	3.0	14
58	New prospects for PCSK9 inhibition?. <i>European Heart Journal</i> , 2018, 39, 2600-2601.	2.2	13
59	Redefining cardiovascular risk prediction: is the crystal ball clearer now?. <i>European Heart Journal</i> , 2021, 42, 2468-2471.	2.2	13
60	Chasing LDL cholesterol to the bottom – PCSK9 in perspective. , 2022, 1, 554-561.		13
61	Association of dietary and gut microbiota-related metabolites with calcific aortic stenosis. <i>Acta Cardiologica</i> , 2021, 76, 544-552.	0.9	10
62	Cost of heart failure management in Turkey: results of a Delphi Panel. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 554-562.	0.9	10
63	Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 801-808.	2.6	9
64	Lipid Clinics Network. Rationale and design of the EAS global project. <i>Atherosclerosis Supplements</i> , 2020, 42, e6-e8.	1.2	9
65	The year in cardiovascular medicine 2021: dyslipidaemia. <i>European Heart Journal</i> , 2022, , .	2.2	9
66	Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry). <i>Journal of Clinical Lipidology</i> , 2020, 14, 361-370.e2.	1.5	8
67	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 2030-2037.	1.8	8
68	Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 agenda to fight atherosclerotic cardiovascular disease in Europe. <i>Atherosclerosis</i> , 2021, 322, 77-81.	0.8	8
69	Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. <i>Atherosclerosis</i> , 2021, 338, 55-63.	0.8	8
70	The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutation. <i>Neuromuscular Disorders</i> , 2022, 32, 50-56.	0.6	8
71	Implementation, target population, compliance and barriers to risk guided therapy. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 37-41.	1.8	7
72	Can EPA evaporate plaques?. <i>European Heart Journal</i> , 2020, 41, 3933-3935.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Patient characteristics and statin discontinuation-related factors during treatment of hypercholesterolemia: an observational non-interventional study in patients with statin discontinuation (STAY study). <i>Turk Kardiyoloji Dernegi Arsivi</i> , 2016, 44, 53-64.	0.5	6
74	Pre- and in-hospital antithrombotic management patterns and in-hospital outcomes in patients with acute coronary syndrome: data from the Turkish arm of the EPICOR study. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 900-915.	0.9	6
75	Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey: Follow up data for mortality. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 160-168.	0.9	6
76	Diet, Lifestyle, Smoking. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	5
77	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020, 42, e1-e5.	1.2	5
78	Prevention guidelines and EAS/ESC guidelines for the treatment of dyslipidaemias: A look to the future. <i>Atherosclerosis</i> , 2022, 340, 51-52.	0.8	5
79	The challenge of risk prediction: How good are we?. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 418-419.	1.8	4
80	Transatlantic Lipid Guideline Divergence: Same Data But Different Interpretations. <i>Journal of the American Heart Association</i> , 2020, 9, e018189.	3.7	4
81	Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2017, 17, 19-31.	1.2	3
82	Is there a gender gap in secondary prevention of coronary artery disease in Turkey?. <i>Turk Kardiyoloji Dernegi Arsivi</i> , 2018, 46, 683-691.	0.2	3
83	In-hospital statin initiation characteristics and one-year statin adherence rates in patients hospitalised for acute coronary syndrome. <i>Acta Cardiologica</i> , 2020, 76, 1-7.	0.9	2
84	Should We Target Global Risk or Risk Factors?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 2.	4.8	2
85	Evaluation of internal medicine physicians' attitudes toward the treatment of dyslipidemia. <i>Postgraduate Medicine</i> , 2020, 132, 538-543.	2.0	1
86	Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis. <i>Atherosclerosis Plus</i> , 2021, 44, 18-18.	0.7	1
87	Demographics of patients ≥ 80 years with heart failure who were admitted to the cardiology clinics in Turkey. <i>Anatolian Journal of Cardiology</i> , 2019, 21, 196-205.	0.9	1
88	How Did The Updated Haemodynamic Definitions Affect The Frequency Of Pulmonary Hypertension In Patients With Systemic Sclerosis?. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 30-35.	0.9	1
89	An updated perspective and pooled analysis of Cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. <i>Anatolian Journal of Cardiology</i> , 2020, 25, 61-76.	0.9	1
90	Correlation of tissue selectin expression and hemodynamic parameters in rheumatic mitral valve disease. <i>Journal of Heart Valve Disease</i> , 2006, 15, 671-8.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Successful pregnancy by in vitro fertilization after Mustard operation for transposition of the great arteries. <i>Journal of Cardiology Cases</i> , 2011, 3, e50-e52.	0.5	0
92	Which patients have the highest cardiovascular risk? A follow-up study from Turkey. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 250-256.	2.8	0
93	EdÄ±torÄ±al. <i>Anatolian Journal of Cardiology</i> , 2015, 15, XII.	0.9	0
94	The new Dyslipidaemia Team of the <i>European Heart Journal</i>. <i>European Heart Journal</i> , 2020, 41, 3870-3871.	2.2	0